Literature DB >> 26026195

Design, recruitment, and microbiological considerations in human challenge studies.

Thomas C Darton1, Christoph J Blohmke2, Vasee S Moorthy3, Daniel M Altmann4, Frederick G Hayden5, Elizabeth A Clutterbuck1, Myron M Levine6, Adrian V S Hill7, Andrew J Pollard1.   

Abstract

Since the 18th century a wealth of knowledge regarding infectious disease pathogenesis, prevention, and treatment has been accumulated from findings of infection challenges in human beings. Partly because of improvements to ethical and regulatory guidance, human challenge studies-involving the deliberate exposure of participants to infectious substances-have had a resurgence in popularity in the past few years, in particular for the assessment of vaccines. To provide an overview of the potential use of challenge models, we present historical reports and contemporary views from experts in this type of research. A range of challenge models and practical approaches to generate important data exist and are used to expedite vaccine and therapeutic development and to support public health modelling and interventions. Although human challenge studies provide a unique opportunity to address complex research questions, participant and investigator safety is paramount. To increase the collaborative effort and future success of this area of research, we recommend the development of consensus frameworks and sharing of best practices between investigators. Furthermore, standardisation of challenge procedures and regulatory guidance will help with the feasibility for using challenge models in clinical testing of new disease intervention strategies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26026195     DOI: 10.1016/S1473-3099(15)00068-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  43 in total

Review 1.  The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG.

Authors:  David Skurnik; Colette Cywes-Bentley; Gerald B Pier
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

2.  Reply to Bernstein, Atmar, and Hoft.

Authors:  Alison Han; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

Review 3.  Distinct and complementary roles of CD4 T cells in protective immunity to influenza virus.

Authors:  Andrea J Sant; Katherine A Richards; Jennifer Nayak
Journal:  Curr Opin Immunol       Date:  2018-04-02       Impact factor: 7.486

4.  A Class I Haemophilus ducreyi Strain Containing a Class II hgbA Allele Is Partially Attenuated in Humans: Implications for HgbA Vaccine Efficacy Trials.

Authors:  Isabelle Leduc; Kate R Fortney; Diane M Janowicz; Beth Zwickl; Sheila Ellinger; Barry P Katz; Huaiying Lin; Qunfeng Dong; Stanley M Spinola
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

5.  Ethical challenges posed by human infection challenge studies in endemic settings.

Authors:  Michael J Selgelid; Euzebiusz Jamrozik
Journal:  Indian J Med Ethics       Date:  2018-09-18

Review 6.  Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2.

Authors:  Ian McDonald; Sam M Murray; Catherine J Reynolds; Daniel M Altmann; Rosemary J Boyton
Journal:  NPJ Vaccines       Date:  2021-05-13       Impact factor: 7.344

Review 7.  Animal models for dissecting Vibrio cholerae intestinal pathogenesis and immunity.

Authors:  Brandon Sit; Bolutife Fakoya; Matthew K Waldor
Journal:  Curr Opin Microbiol       Date:  2021-10-22       Impact factor: 7.934

8.  Nontoxigenic Vibrio cholerae Challenge Strains for Evaluating Vaccine Efficacy and Inferring Mechanisms of Protection.

Authors:  Bolutife Fakoya; Karthik Hullahalli; Daniel H F Rubin; Deborah R Leitner; Roma Chilengi; David A Sack; Matthew K Waldor
Journal:  mBio       Date:  2022-04-07       Impact factor: 7.786

9.  Clinical trials: The mathematics of falling vaccine efficacy with rising disease incidence.

Authors:  M Gabriela M Gomes; Stephen B Gordon; David G Lalloo
Journal:  Vaccine       Date:  2016-05-10       Impact factor: 3.641

10.  Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.

Authors:  Thomas C Darton; Claire Jones; Christoph J Blohmke; Claire S Waddington; Liqing Zhou; Anna Peters; Kathryn Haworth; Rebecca Sie; Christopher A Green; Catherine A Jeppesen; Maria Moore; Ben A V Thompson; Tessa John; Robert A Kingsley; Ly-Mee Yu; Merryn Voysey; Zoe Hindle; Stephen Lockhart; Marcelo B Sztein; Gordon Dougan; Brian Angus; Myron M Levine; Andrew J Pollard
Journal:  PLoS Negl Trop Dis       Date:  2016-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.